Rompianesi G, Pegoraro F, Ceresa CD, Montalti R, Troisi RI. Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases. World J Gastroenterol 2022; 28(1): 108-122 [PMID: PMC8793013 DOI: 10.3748/wjg.v28.i1.108]
Corresponding Author of This Article
Gianluca Rompianesi, FEBS, MD, PhD, Assistant Professor, Surgeon, Division of Hepato-Bilio-Pancreatic, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, via Pansini 5, Naples 80125, Italy. gianlucarompianesi@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 7, 2022; 28(1): 108-122 Published online Jan 7, 2022. doi: 10.3748/wjg.v28.i1.108
Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases
Gianluca Rompianesi, Francesca Pegoraro, Carlo DL Ceresa, Roberto Montalti, Roberto Ivan Troisi
Gianluca Rompianesi, Francesca Pegoraro, Roberto Ivan Troisi, Division of Hepato-Bilio-Pancreatic, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples 80125, Italy
Carlo DL Ceresa, Department of Hepato-Pancreato-Biliary Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9ES, United Kingdom
Roberto Montalti, Division of Hepato-Bilio-Pancreatic, Minimally Invasive and Robotic Surgery, Department of Public Health, Federico II University Hospital, Naples 80125, Italy
Author contributions: Rompianesi G conceptualized the manuscript; Rompianesi G and Montalti R wrote the manuscript; Pegoraro F performed the literature search and the data analysis and extraction; Ceresa CDL and Troisi RI reviewed and edited the manuscript; and all authors have read and approve the final manuscript.
Conflict-of-interest statement: No Author has any conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gianluca Rompianesi, FEBS, MD, PhD, Assistant Professor, Surgeon, Division of Hepato-Bilio-Pancreatic, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, via Pansini 5, Naples 80125, Italy. gianlucarompianesi@gmail.com
Received: August 13, 2021 Peer-review started: August 13, 2021 First decision: October 2, 2021 Revised: October 12, 2021 Accepted: December 25, 2021 Article in press: December 25, 2021 Published online: January 7, 2022 Processing time: 140 Days and 2.2 Hours
Abstract
Colorectal cancer (CRC) is the third most common malignancy worldwide, with approximately 50% of patients developing colorectal cancer liver metastasis (CRLM) during the follow-up period. Management of CRLM is best achieved via a multidisciplinary approach and the diagnostic and therapeutic decision-making process is complex. In order to optimize patients’ survival and quality of life, there are several unsolved challenges which must be overcome. These primarily include a timely diagnosis and the identification of reliable prognostic factors. Furthermore, to allow optimal treatment options, a precision-medicine, personalized approach is required. The widespread digitalization of healthcare generates a vast amount of data and together with accessible high-performance computing, artificial intelligence (AI) technologies can be applied. By increasing diagnostic accuracy, reducing timings and costs, the application of AI could help mitigate the current shortcomings in CRLM management. In this review we explore the available evidence of the possible role of AI in all phases of the CRLM natural history. Radiomics analysis and convolutional neural networks (CNN) which combine computed tomography (CT) images with clinical data have been developed to predict CRLM development in CRC patients. AI models have also proven themselves to perform similarly or better than expert radiologists in detecting CRLM on CT and magnetic resonance scans or identifying them from the noninvasive analysis of patients’ exhaled air. The application of AI and machine learning (ML) in diagnosing CRLM has also been extended to histopathological examination in order to rapidly and accurately identify CRLM tissue and its different histopathological growth patterns. ML and CNN have shown good accuracy in predicting response to chemotherapy, early local tumor progression after ablation treatment, and patient survival after surgical treatment or chemotherapy. Despite the initial enthusiasm and the accumulating evidence, AI technologies’ role in healthcare and CRLM management is not yet fully established. Its limitations mainly concern safety and the lack of regulation and ethical considerations. AI is unlikely to fully replace any human role but could be actively integrated to facilitate physicians in their everyday practice. Moving towards a personalized and evidence-based patient approach and management, further larger, prospective and rigorous studies evaluating AI technologies in patients at risk or affected by CRLM are needed.
Core tip: The digitalization of healthcare generating huge amount of data set the ground for the progressive ubiquitous application of artificial intelligence (AI) technologies in healthcare. AI analyses can assist clinicians in all phases of colorectal liver metastases natural history: From predicting their occurrence, to increasing diagnostic accuracy or estimating recurrence risk after treatment and patient outcome. The implementation of AI resources supports the contemporary paradigm shift that sees healthcare focus moving from a generalized, disease-oriented to an individual, patient-centered, precision medicine approach.